Market Sentiment Around Loss-Making Appili Therapeutics Inc. (TSE:APLI)

We feel now is a pretty good time to analyse Appili Therapeutics Inc.'s (TSE:APLI) business as it appears the company may be on the cusp of a considerable accomplishment. Appili Therapeutics Inc., a biopharmaceutical company, acquires, develops, and commercializes novel medicines for unmet needs in the infectious disease in Canada. With the latest financial year loss of CA$5.4m and a trailing-twelve-month loss of CA$11m, the CA$64m market-cap company amplified its loss by moving further away from its breakeven target. Many investors are wondering about the rate at which Appili Therapeutics will turn a profit, with the big question being “when will the company breakeven?” We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

Check out our latest analysis for Appili Therapeutics

Appili Therapeutics is bordering on breakeven, according to the 5 Canadian Pharmaceuticals analysts. They anticipate the company to incur a final loss in 2021, before generating positive profits of CA$19m in 2022. Therefore, the company is expected to breakeven just over a year from now. How fast will the company have to grow each year in order to reach the breakeven point by 2022? Working backwards from analyst estimates, it turns out that they expect the company to grow 41% year-on-year, on average, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.

Underlying developments driving Appili Therapeutics' growth isn’t the focus of this broad overview, though, bear in mind that by and large a pharma company has lumpy cash flows which are contingent on the drug and stage of product development the business is in. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

Before we wrap up, there’s one aspect worth mentioning. The company has managed its capital judiciously, with debt making up 6.0% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

This article is not intended to be a comprehensive analysis on Appili Therapeutics, so if you are interested in understanding the company at a deeper level, take a look at Appili Therapeutics' company page on Simply Wall St. We've also compiled a list of important factors you should further research:

1. Valuation: What is Appili Therapeutics worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Appili Therapeutics is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Appili Therapeutics’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

If you decide to trade Appili Therapeutics, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
^*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.